News Press Releases

Medican Enters Into An Agreement with Music Quest Entertainment Studio

MDCN | August 4, 2015

Medican Enterprises, Inc. (OTCBB:MDCN) a bio-pharmaceutical company focused on developing, and marketing pharmaceutical grade cannabis to the emerging global medical marijuana market is pleased to announce a strategic sales marketing plan with Music Quest Entertainment.

After an extensive, year long evaluation of different strategic opportunities to produce active sales, the changes that we are instituting will assure that Medican Enterprises will accelerate delivering high quality products and sales.

“As the company moves forward, we are profoundly grateful for our old and new advisers’ guidance and support that has been offered over the last several months,” said Ken Williams, CEO.

The investments in sales opportunities have positioned the company for our next level of growth and success which includes; Michigan Investment Property, Wine products, and the automated natural light cannabis grow facilities. As contracts are signed, construction will begin early October.

We have just entered into a Memo of Understanding with a leading media marketing group out of Chicago, Music Quest (www.musicqe.com) for the celebrity promotion and marketing of D420. Our branded Moscato Wine to be produced, labeled and distributed in collaboration with Newealth US, Inc. The first cases/bottles of wine will be shipped within the next 5 weeks. This venture will establish a market share within the trillion-dollar African American retail entertainment community. To further the potential of capturing this market segment Medican, Newealth and Music Quest are in the final stages of launching a live stream internet network for production and distribution of movies, artist videos (established and new), weekly series, live feeds from concerts, clubs, auctions, documentaries, news and more.

All of these investments have been secured mostly through extensive collaboration with Newealth and Music Quest so capital outlay has been minimal. Again, sales offer the best path towards success for Medican and we are currently on that path.

Thank you for your patience we will see improvement to our bottom line starting this month.

About Medican Enterprises Inc.
Medican Enterprises is a bio-pharmaceutical company focused on developing, distributing and marketing pharmaceutical grade cannabis to the emerging global medical marijuana market. It’s wholly owned subsidiary Medican Systems Inc. is an industry leader in the design, construction and operation of Medical Marijuana and Cultivation Centers across Canada. For more information visit: http://medican.enterprises

Forward-Looking and Cautionary Statements
Certain statements contained herein contain “forward-looking statements” within the meaning of Section 27A of Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medican Enterprises Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Medican Enterprises Inc. disclaims any obligation to update or to announce publicly the results of any revision of the forward-looking statements contained or incorporated by reference herein to reflect future events or developments. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.